- Conditions
- Influenza
- Interventions
- Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 74
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- 2% Lidocaine HCl topical solution, 0.9% Sodium chloride
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- HS110 vaccine, Placebo
- Biological
- Lead sponsor
- Heat Biologics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Egg Allergy
- Interventions
- Trivalent Influenza Vaccine
- Biological
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 6 Months to 24 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- Matrix-M2, GEN-003, Placebo
- Biological · Drug
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
- Conditions
- Autistic Disorder
- Interventions
- Fluoxetine, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 30 Months to 58 Months
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- New York, New York • Chapel Hill, North Carolina
- Conditions
- Zika Virus Infection
- Interventions
- IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,390 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
- Conditions
- Endometriosis, Adenomyosis, Chronic Pelvic Inflammatory Disease
- Interventions
- Custom-formulated, high-CBD study product, Placebo
- Drug
- Lead sponsor
- Staci Gruber, Ph.D.
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Typhoid Vi Polysaccharide Vaccine, Placebo
- Biological
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 30 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Urinary Bladder, Overactive, Pelvic Organ Prolapse
- Interventions
- OnabotulinumtoxinA 100 UNT, Injectable saline
- Drug · Other
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anthrax
- Interventions
- AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
- Biological
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
- Conditions
- Influenza
- Interventions
- 13 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 59 Years
- Enrollment
- 1,116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Rolling Hills Estates, California • Aurora, Colorado + 29 more
- Conditions
- Idiopathic Intracranial Hypertension (IIH)
- Interventions
- Tirzepatide, Tirzepatide Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
- Interventions
- Engensis (VM202), placebo
- Biological · Other
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 22 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lyophilized albiglutide DCC pen injector, Lyophilized albiglutide DCC pen injector matching placebo, Albiglutide liquid auto-injector, Albiglutide liquid auto-injector matching placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Ropivacaine, Ketorolac, Clonidine, Epinephrine, 0.9% sodium chloride
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Zika Virus
- Interventions
- Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of placebo via subcutaneous injection (0.5ml)., Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Burlington, Vermont
- Conditions
- HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
- Interventions
- Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- HIV Infections, Smallpox
- Interventions
- MVA Smallpox Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Saline Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,599 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
- Conditions
- Healthy
- Interventions
- MEDI3414 [Influenza A/H1N1 live attenuated, intranasal], Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Daytona Beach, Florida • Miami, Florida • South Miami, Florida + 2 more
- Conditions
- NLRC4-MAS, XIAP Deficiency
- Interventions
- Tadekinig alfa, 0.9% sodium chloride
- Drug · Other
- Lead sponsor
- AB2 Bio Ltd.
- Industry
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
- Interventions
- Bevacizumab, Placebo (Saline)
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California